Experience

Davis Polk advised Affimed N.V. on its $26.5 million public offering of 13,225,000 of its common shares. Included in the shares are 1,725,000 shares sold by Affimed pursuant to the…

Davis Polk is advising Charles River Laboratories International, Inc. on its approximately $800 million acquisition of MPI Research Inc. The transaction, which is expected to close early in…

Davis Polk advised the joint book-running managers and representatives of the underwriters in connection with an SEC-registered offering by Seattle Genetics, Inc. of 13,269,230 shares…

Davis Polk advised the joint book-running managers in connection with the $133.7 million initial public offering of common stock of Solid Biosciences Inc. The common stock is listed on the…

Davis Polk advised the joint book-running managers and representatives of the underwriters in connection with the SEC-registered offering of 13,333,333 shares of common stock of ConforMis,…

Davis Polk advised the joint book-running managers in connection with a $115 million SEC-registered offering of 5,897,435 shares of common stock of Five Prime Therapeutics, Inc. The…

Davis Polk advised the joint book-running managers in connection with a $124.5 million SEC-registered follow-on offering of 3,000,000 shares of common stock of Adamas Pharmaceuticals, Inc…

Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with the SEC-registered offering of 4,255,000 shares of common stock of…

Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with the SEC-registered offering of 8,152,986 shares of common stock of…

Davis Polk advised the joint book-running managers and representatives of the underwriters in the $800 million public offering by BeiGene, Ltd. of American depositary shares. The ADSs are…